Its defining feature is convenience: a twice-yearly, every-six-months subcutaneous dose. However, the regulatory picture is not uniform across a second indication. Chronic rhinosinusitis with nasal polyps (CRSwNP) is approved in the UK and EU but received a Complete Response Letter from the US Food …
Jemperli is approved in the UK, EU and US for endometrial cancer, both as a monotherapy for pre-treated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) disease and, separately, in a first-line combination with platinum chemotherapy that has been broadened to an all-comer population. The US …
For investors, the central question is why this franchise matters. Dolutegravir-based regimens sit at the core of GSK's Specialty Medicines HIV business, a material contributor to group revenue. GSK retains a 78.3% economic interest in ViiV Healthcare following 2026 shareholding changes. This article examines …
This article explains what abacavir is, how GSK is connected to it via ViiV Healthcare, and why that structure matters. It also sets out important safety context — in particular the need for HLA-B*5701 genetic testing before use — using reliable approved sources, and …
In the first setting it is approved as monotherapy for pre-treated recurrent or advanced disease that is mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H). In the second, it is approved in combination with platinum-containing chemotherapy for first-line primary advanced or recurrent disease, a combination indication that …
This article explains what aciclovir is in this consumer context, how Haleon is connected to it, and — importantly — how the consumer Zovirax range differs from prescription-only aciclovir medicines supplied by other companies. It distinguishes clinical facts from commercial analysis and does not …
AstraZeneca plc (LSE:AZN) markets Saphnelo (anifrolumab), a biologic medicine used in the treatment of systemic lupus erythematosus (SLE). Saphnelo is approved as an add-on therapy for certain adults with moderate-to-severe, autoantibody-positive SLE who are already receiving standard treatment, according to the approved product information. …
This article explains what Calquence is, how acalabrutinib works, which approved indications apply in the UK, and why the product matters commercially to AstraZeneca. It also separates what an MHRA active-substance listing does and does not establish, and it sets out the principal clinical, …
Forxiga is the UK and European brand name for dapagliflozin, an oral medicine developed and now wholly owned by AstraZeneca plc (LSE:AZN); the same molecule is sold in the United States as Farxiga. It belongs to a class known as sodium-glucose co-transporter 2 (SGLT2) …
AstraZeneca plc (LSE:AZN) is pursuing broader cardiorenal growth by positioning its dapagliflozin-based medicine Forxiga (US brand Farxiga) at the intersection of heart, kidney and metabolic disease. The central question for investors is whether that strategy can sustain demand now that the medicine's core patent …